JP7807238B2 - 骨形成タンパク質６に対するヒト抗体 - Google Patents

骨形成タンパク質６に対するヒト抗体

Info

Publication number
JP7807238B2
JP7807238B2 JP2021573449A JP2021573449A JP7807238B2 JP 7807238 B2 JP7807238 B2 JP 7807238B2 JP 2021573449 A JP2021573449 A JP 2021573449A JP 2021573449 A JP2021573449 A JP 2021573449A JP 7807238 B2 JP7807238 B2 JP 7807238B2
Authority
JP
Japan
Prior art keywords
antibody
bmp6
antigen
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021573449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537142A5 (https=
JPWO2020251924A5 (https=
JP2022537142A (ja
Inventor
サラ ジェイ． ハットセル，
ヴィンセント ジェイ． イドン，
アンドリュー ジェイ． マーフィー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022537142A publication Critical patent/JP2022537142A/ja
Publication of JP2022537142A5 publication Critical patent/JP2022537142A5/ja
Publication of JPWO2020251924A5 publication Critical patent/JPWO2020251924A5/ja
Priority to JP2025112473A priority Critical patent/JP2025138816A/ja
Application granted granted Critical
Publication of JP7807238B2 publication Critical patent/JP7807238B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021573449A 2019-06-12 2020-06-09 骨形成タンパク質６に対するヒト抗体 Active JP7807238B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025112473A JP2025138816A (ja) 2019-06-12 2025-07-02 骨形成タンパク質６に対するヒト抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962860597P 2019-06-12 2019-06-12
US62/860,597 2019-06-12
PCT/US2020/036771 WO2020251924A1 (en) 2019-06-12 2020-06-09 Human antibodies to bone morphogenetic protein 6

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025112473A Division JP2025138816A (ja) 2019-06-12 2025-07-02 骨形成タンパク質６に対するヒト抗体

Publications (4)

Publication Number Publication Date
JP2022537142A JP2022537142A (ja) 2022-08-24
JP2022537142A5 JP2022537142A5 (https=) 2023-06-15
JPWO2020251924A5 JPWO2020251924A5 (https=) 2023-06-15
JP7807238B2 true JP7807238B2 (ja) 2026-01-27

Family

ID=71944214

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573449A Active JP7807238B2 (ja) 2019-06-12 2020-06-09 骨形成タンパク質６に対するヒト抗体
JP2025112473A Pending JP2025138816A (ja) 2019-06-12 2025-07-02 骨形成タンパク質６に対するヒト抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025112473A Pending JP2025138816A (ja) 2019-06-12 2025-07-02 骨形成タンパク質６に対するヒト抗体

Country Status (6)

Country Link
EP (1) EP3983436A1 (https=)
JP (2) JP7807238B2 (https=)
AU (1) AU2020292246A1 (https=)
CA (1) CA3141266A1 (https=)
MA (1) MA56203A (https=)
WO (1) WO2020251924A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140199314A1 (en) 2008-12-29 2014-07-17 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation of bmp-6
JP2016501273A (ja) 2012-12-17 2016-01-18 イーライ リリー アンド カンパニー Ｂｍｐ−６抗体
WO2017191437A1 (en) 2016-05-03 2017-11-09 Kymab Limited Methods, regimens, combinations & antagonists
JP2018504893A (ja) 2014-12-19 2018-02-22 ノバルティス アーゲー Ｂｍｐ６を標的とする抗体のための組成物および方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
EP2136788B1 (en) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
AU2016211890B2 (en) * 2008-11-13 2018-03-22 The General Hospital Corporation Methods and Compositions for Regulating Iron Homeostasis by Modulation of BMP-6

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140199314A1 (en) 2008-12-29 2014-07-17 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation of bmp-6
JP2016501273A (ja) 2012-12-17 2016-01-18 イーライ リリー アンド カンパニー Ｂｍｐ−６抗体
JP2018504893A (ja) 2014-12-19 2018-02-22 ノバルティス アーゲー Ｂｍｐ６を標的とする抗体のための組成物および方法
WO2017191437A1 (en) 2016-05-03 2017-11-09 Kymab Limited Methods, regimens, combinations & antagonists

Also Published As

Publication number Publication date
EP3983436A1 (en) 2022-04-20
MA56203A (fr) 2022-04-20
US20220251184A1 (en) 2022-08-11
CA3141266A1 (en) 2020-12-17
AU2020292246A1 (en) 2022-01-27
WO2020251924A1 (en) 2020-12-17
JP2025138816A (ja) 2025-09-25
JP2022537142A (ja) 2022-08-24

Similar Documents

Publication Publication Date Title
US20230192831A1 (en) Human Antibodies to GREM1
US11571482B2 (en) Human antibodies to S. aureus Hemolysin A toxin
US10526403B2 (en) Anti-activin A antibodies and uses thereof
AU2015264189B2 (en) Human antibodies to Middle East Respiratory Syndrome -Coronavirus spike protein
JP7034068B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
CA2993976A1 (en) Anti-angptl8 antibodies and uses thereof
US20240190974A1 (en) Anti-acvr1 antibodies and uses thereof
CN112437682B (zh) 抗因子XII/XIIa抗体和其用途
JP7807238B2 (ja) 骨形成タンパク質６に対するヒト抗体
US12612452B2 (en) Human antibodies to bone morphogenetic protein 6
US20260000758A1 (en) Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof
US9751936B2 (en) Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense
EA041355B1 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА К ТОКСИНУ ГЕМОЛИЗИНУ А S.aureus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230607

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260115

R150 Certificate of patent or registration of utility model

Ref document number: 7807238

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150